These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28616586)

  • 1. The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer.
    Erstad DJ; Tager AM; Hoshida Y; Fuchs BC
    Mol Cell Oncol; 2017; 4(3):e1311827. PubMed ID: 28616586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer.
    Kaffe E; Magkrioti C; Aidinis V
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31652837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.
    Farquhar MJ; Humphreys IS; Rudge SA; Wilson GK; Bhattacharya B; Ciaccia M; Hu K; Zhang Q; Mailly L; Reynolds GM; Ashcroft M; Balfe P; Baumert TF; Roessler S; Wakelam MJO; McKeating JA
    J Hepatol; 2017 May; 66(5):919-929. PubMed ID: 28126468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of the lysophosphatidic acid signaling axis in liver cancer.
    Lopane C; Agosti P; Gigante I; Sabbà C; Mazzocca A
    Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):277-282. PubMed ID: 28591560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Concentrations of Lysophosphatidic Acid and Autotaxin in Abstinent Patients with Alcohol Use Disorder and Comorbid Liver Disease.
    Flores-López M; García-Marchena N; Pavon FJ; Lara E; Porras-Perales O; Araos P; Requena-Ocaña N; Torres-Galván S; Mañas-Padilla MC; Rubio G; Suárez J; Santín LJ; Rodríguez de Fonseca F; Castilla-Ortega E; García-Fernández MI; Serrano A
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis.
    Baader M; Bretschneider T; Broermann A; Rippmann JF; Stierstorfer B; Kuttruff CA; Mark M
    Br J Pharmacol; 2018 Feb; 175(4):693-707. PubMed ID: 29197066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of Autotaxin/Autotaxin-Lysophosphatidic Acid Axis in the Initiation and Progression of Liver Cancer.
    She S; Zhang Q; Shi J; Yang F; Dai K
    Front Oncol; 2022; 12():922945. PubMed ID: 35769713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte autotaxin expression promotes liver fibrosis and cancer.
    Kaffe E; Katsifa A; Xylourgidis N; Ninou I; Zannikou M; Harokopos V; Foka P; Dimitriadis A; Evangelou K; Moulas AN; Georgopoulou U; Gorgoulis VG; Dalekos GN; Aidinis V
    Hepatology; 2017 Apr; 65(4):1369-1383. PubMed ID: 27981605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels.
    Enooku K; Uranbileg B; Ikeda H; Kurano M; Sato M; Kudo H; Maki H; Koike K; Hasegawa K; Kokudo N; Yatomi Y
    PLoS One; 2016; 11(9):e0161825. PubMed ID: 27583415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autotaxin in liver fibrosis.
    Ikeda H; Yatomi Y
    Clin Chim Acta; 2012 Nov; 413(23-24):1817-21. PubMed ID: 22820036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression.
    Park SY; Jeong KJ; Panupinthu N; Yu S; Lee J; Han JW; Kim JM; Lee JS; Kang J; Park CG; Mills GB; Lee HY
    Oncogene; 2011 Mar; 30(11):1351-9. PubMed ID: 21102517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased serum autotaxin levels in hepatocellular carcinoma patients were caused by background liver fibrosis but not by carcinoma.
    Kondo M; Ishizawa T; Enooku K; Tokuhara Y; Ohkawa R; Uranbileg B; Nakagawa H; Tateishi R; Yoshida H; Kokudo N; Koike K; Yatomi Y; Ikeda H
    Clin Chim Acta; 2014 Jun; 433():128-34. PubMed ID: 24642343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro.
    Schmid R; Wolf K; Robering JW; Strauß S; Strissel PL; Strick R; Rübner M; Fasching PA; Horch RE; Kremer AE; Boos AM; Weigand A
    BMC Cancer; 2018 Dec; 18(1):1273. PubMed ID: 30567518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.
    Bain G; Shannon KE; Huang F; Darlington J; Goulet L; Prodanovich P; Ma GL; Santini AM; Stein AJ; Lonergan D; King CD; Calderon I; Lai A; Hutchinson JH; Evans JF
    J Pharmacol Exp Ther; 2017 Jan; 360(1):1-13. PubMed ID: 27754931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma.
    Wu JM; Xu Y; Skill NJ; Sheng H; Zhao Z; Yu M; Saxena R; Maluccio MA
    Mol Cancer; 2010 Mar; 9():71. PubMed ID: 20356387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.
    David M; Wannecq E; Descotes F; Jansen S; Deux B; Ribeiro J; Serre CM; Grès S; Bendriss-Vermare N; Bollen M; Saez S; Aoki J; Saulnier-Blache JS; Clézardin P; Peyruchaud O
    PLoS One; 2010 Mar; 5(3):e9741. PubMed ID: 20305819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autotaxin in Pathophysiology and Pulmonary Fibrosis.
    Ninou I; Magkrioti C; Aidinis V
    Front Med (Lausanne); 2018; 5():180. PubMed ID: 29951481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Expression Regulation and Biological Function of Autotaxin.
    Zhang X; Li M; Yin N; Zhang J
    Cells; 2021 Apr; 10(4):. PubMed ID: 33921676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated Autotaxin and LPA Levels During Chronic Viral Hepatitis and Hepatocellular Carcinoma Associate with Systemic Immune Activation.
    Kostadinova L; Shive CL; Anthony DD
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31769428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis.
    Budd DC; Qian Y
    Future Med Chem; 2013 Oct; 5(16):1935-52. PubMed ID: 24175745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.